Exercise vs. Topical Diclofenac vs. PRP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-20

Study Completion Date

2025-05-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Osteoarthritis, the most common type of arthritis, is a chronic and degenerative joint disease. It has been reported to affect more than 300 million adults and elderly individuals worldwide. The joint most commonly affected by osteoarthritis is the knee joint and this condition is called gonarthrosis.

The goal of treatment is to reduce symptoms and ultimately slow the progression of the disease with various treatment options throughout the course of the disease.Current clinical studies prepared by the working groups of the International Osteoarthritis Research Society (OARSI) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) According to the guidelines, treatment typically includes physiotherapy interventions with the use of non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, including intra-articular injections of corticosteroids. Exercise-oriented physiotherapy is one of the main approaches for the conservative treatment of gonarthrosis. The curative clinical effect of exercise therapy on pain and functional disability in gonarthrosis is important.

The use of PRP in the treatment of gonarthrosis is based on the ability of platelets to release biologically active proteins and promote tissue healing. Since the cartilage tissue mainly affected in gonarthrosis has low healing potential, this feature of platelets becomes more important for the target tissue. Existing studies show that PRP is superior to hyaluronic acid in intermediate and initial gonarthrosis; on the other hand, less satisfactory results are reported in severe gonarthrosis, similar to viscosupplementation.

Topically or orally administered NSAIDs form the backbone of pharmacological treatment in gonarthrosis.

It is seen that both exercise, PRP and topical NSAID agents are among the recommendations in the treatment of gonarthrosis. However, there is insufficient evidence regarding the superiority and therapeutic efficacy of these three treatment approaches. The aim of this study is to determine the effectiveness of "exercise", "PRP" and "NSAID-specific topical agents" in the treatment of patients with gonarthrosis; pain, function, quality of life, and patient satisfaction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PRP Effectiveness in Knee Osteoarthritis

NCT04807270

Knee Osteoarthritis

UNKNOWN NA

Home-Based Strategies for Knee Osteoarthritis

NCT07212647

Knee Osteoarthritis Knee Osteoarthritis (Knee OA)

RECRUITING NA

The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee

NCT01926327

Osteoarthritis

COMPLETED PHASE3

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01461369

Osteoarthritis

COMPLETED PHASE3

Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis

NCT02588872

Osteoarthritis, Knee

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Voluntary participants who have been diagnosed with gonarthritis will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into tree groups. Study groups will be as follows: a) exercise, b) topical diclofenac, c) platalet-rich-plasma (PRP).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gonarthrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

The investigator administering the treatment and the investigator performing the evaluations will be different. The evaluator will not know about the interventions that the participants received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group 1

The patients in the Exercise group will be treated with a structured exercise program. The exercises will be applied by the research physiotherapist for 6 weeks, 2 days a week. Each training session is planned to last approximately 30 minutes.

Group Type ACTIVE_COMPARATOR

Exercise

Intervention Type OTHER

The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.

Intervention Group 2

The patients in the topical agent group were prescribed by the orthopedist. they will use the topical agent. Diclofenac in gel form was chosen as a topical agent in the light of the literature. In this context, patients in both groups will apply the topical agent around the knee joint 4 days a week, 2 times a day (every 12 hours) in the morning and evening for 6 weeks.

Group Type ACTIVE_COMPARATOR

Topical Diclofenac

Intervention Type OTHER

They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.

Intervention Group 3

The PRP procedure with the same characteristics will be used in the treatment of patients in the PRP group. The PRP application will be prepared by the orthopedics and traumatology specialist physician in the research team, using the kits provided within the scope of the project. In order to collect venous blood for the PRP production procedure, gamma sterile vacuum tubes and blood collection set in special kits without the risk of contamination will be used. A total of 3 doses will be administered to the patients, with a one-week interval between doses.

Group Type ACTIVE_COMPARATOR

Platelet-Rich-Plasma (PRP)

Intervention Type OTHER

8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.

Intervention Type OTHER

Topical Diclofenac

They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.

Intervention Type OTHER

Platelet-Rich-Plasma (PRP)

8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with gonarthrosis according to the criteria of the American Society of Rheumatology (ACR)
* Stage 2 or 3 according to Kellgren Lawrence radiological staging criteria,
* Those between the ages of 40 and 65,
* Body mass index below 30 kg/m2,
* Pain intensity defined by the patient in the last 3 months is at least 3 out of 10 according to NPRS,
* Patients who do not have any barriers to being included in the exercise program

Exclusion Criteria

* Being in stage 4 according to Kellgren Lawrence radiological staging criteria,
* Hemoglobin level \<11.5 g/dL
* Platelet level \<100,000/μL
* Thrombocytopenia, coagulopathy, crystal arthropathy, hemophilia or hematological malignancy,
* Presence of active infection or tumor,
* Chronic antiaggregant use or taking immunosuppressive therapy,
* Pregnancy or lactation,
* Viscosupplementation or steroid injection in the related knee in the last 3 months, or using systemic steroids,
* To have received a physiotherapy program for the relevant knee in the last 3 months,
* Having a valgus or varus deformity greater than 15°,
* Presence of neurological diseases and/or deformity leading to lower extremity muscle weakness
* Having serious systemic and cardiovascular diseases that interfere with exercise

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No